| Comparison | No. of studies | Effect size (Relative risk/Mean difference) |
|---|---|---|
| Outcome: Infections | ||
| ICS vs. standard treatment | 3 | 0.40 [0.18, 0.87] |
| PCS vs. standard treatment | 1 | 0.15 [0.02, 1.15] |
| ICS + PCS vs. standard treatment | 1 | 0.98[0.14, 6.82] |
| TXA vs. standard treatment | 2 | 0.61 (0.32, 1.18) |
| ICS +TXA vs. TXA | 1 | 1.07 (0.32, 3.60) |
| ICS+PCS+TXA vs. TXA | 1 | 1.31 (0.41, 4.15) |
| Outcome: Thrombotic complications | ||
| TXA vs. standard treatment | 4 | 0.48 (0.18, 1.23) |
| Outcome: Mortality | ||
| ICS vs. standard treatment | 5 | 0.65 (0.27, 1.59) |
| PCS vs. standard treatment | 1 | 3 (0.13, 70.30) |
| ICS + PCS vs. standard treatment | 1 | 0.33 (0.03, 3.09) |
| TXA vs. standard treatment | 17 | 0.52 (0.31, 0.87) |
| ICS + TXA vs. ICS | 1 | 1.04 (0.07, 16.41) |
| ICS + TXA vs. TXA | 1 | 7.71 (0.43, 137.53) |
From: 6, Alternatives to blood transfusion for patients having surgery: Cell salvage and tranexamic acid
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.